Extended-release naltrexone for treatment of alcohol dependence in primary care

Journal of Substance Abuse Treatment

Volumn 39, Issue 1, 2010, Pages 14-21

  Lee, Joshua D ^a,c   Grossman, Ellie ^a,c   DiRocco, Danae ^a,c   Truncali, Andrea ^a,c   Hanley, Kathleen ^a,d   Stevens, David ^a,d   Rotrosen, John ^a,b   Gourevitch, Marc N ^a,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Veterans Administration NYHHS NY   (United States)

^c BELLEVUE HOSPITAL CENTER   (United States)

^d Gouverneur Diagnostic and Treatment Center NY   (United States)

Author keywords

Alcohol medical management; Alcohol pharmacotherapy; Alcohol treatment; Extended release naltrexone; Primary care

Indexed keywords

ACAMPROSATE; ALANINE AMINOTRANSFERASE; ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; DISULFIRAM; NALTREXONE; STEROID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL SKIN REACTION; COHORT ANALYSIS; CONTROLLED DRUG RELEASE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG INDUCED HEADACHE; FATIGUE; FEMALE; FLU LIKE SYNDROME; HELP SEEKING BEHAVIOR; HUMAN; INJECTION; INJECTION SITE ABSCESS; INJECTION SITE CELLULITIS; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; OBSERVATIONAL STUDY; OPEN STUDY; PAIN; PATIENT COUNSELING; PATIENT SATISFACTION; PHYSICIAN; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PRURITUS; PUBLIC HOSPITAL; SIDE EFFECT; SKIN NODULE; SORENESS; SUBSTANCE ABUSE; THERAPY EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URBAN AREA;

ADULT; ALCOHOL DRINKING; ALCOHOLISM; COHORT STUDIES; DELAYED-ACTION PREPARATIONS; FEMALE; HOSPITALS, PUBLIC; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; PATIENT SATISFACTION; PRIMARY HEALTH CARE;

EID: 77953620899     PISSN: 07405472     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsat.2010.03.005     Document Type: Article

References (30)

1. Alexandre P.K., French M.T., Matzger H., Weisner C. Addiction treatment history, medical services utilization, and cost: A longitudinal analysis of problem drinkers. Journal of Addictive Diseases 2006, 25:105-120.
2. Anton R.F., O'Malley S.S., Ciraulo D.A., Cisler R.A., Couper D., Donovan D.M., et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: A randomized controlled trial. Journal of the American Medical Association 2006, 295:2003-2017.
3. Attkisson C.C., Greenfield T.K. The Client Satisfaction Questionnaire (CSQ) Scales and the Service Satisfaction Scale-30 (SSS-30). Outcomes assessment in clinical practice 1996, Williams and Wilkins, Baltimore, MD. L.I. Sederer, B. Dickey (Eds.).
4. Benner J.S., Chapman R.H., Petrilla A.A., Tang S.S., Rosenberg N., Schwartz J.S. Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy. American Journal of Health-System Pharmacy 2009, 66:1471-1477.
5. Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration Alcohol Pharmacotherapies Into Medical Practice. Treatment Improvement Protocol (TIP) Series 49, HHS Publication No. SMA 09-4380 2009, Rockville, MD: DHHS.
6. Davidson D., Palfai T., Bird C., Swift R. Effects of naltrexone on alcohol self-administration in heavy drinkers. Alcoholism: Clinical and Experimental Research 1999, 23:195-203.
7. Del Boca F.K., Darkes J. The validity of self-reports of alcohol consumption: State of the science and challenges for research. Addiction 2003, 98(Suppl 2):1-12.
8. Ellis J.J., Erickson S.R., Stevenson J.G., Bernstein S.J., Stiles R.A., Fendrick A.M. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. Journal of General Internal Medicine 2004, 19:638-645.
9. Ernst D.B., Pettinati H.M., Weiss R.D., Donovan D.M., Longabaugh R. An intervention for treating alcohol dependence: Relating elements of medical management to patient outcomes with implications for primary care. Annals of Family Medicine 2008, 6:435-440.
10. Food and Drug Administration Naltrexone injection site reactions [naltrexone for extended-release injectable suspension (marketed as Vivitrol)]-healthcare professional sheet 2008, FDA Alert (8/12/2008). Retrieved from. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm126446.htm.
11. Garbutt J.C., Kranzler H.R., O'Malley S.S., Gastfriend D.R., Pettinati H.M., Silverman B.L., et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: A randomized controlled trial. Journal of the American Medical Association 2005, 293:1617-1625.
12. Grant B.F., Dawson D.A., Stinson F.S., Chou S.P., Dufour M.C., Pickering R.P. The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002. Drug and Alcohol Dependence 2004, 74:223-234.
13. Hasin D.S., Stinson F.S., Ogburn E., Grant B.F. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Archives of General Psychiatry 2007, 64:830-842.
14. Kranzler H.R., Stephenson J.J., Montejano L., Wang S., Gastfriend D.R. Persistence with oral naltrexone for alcohol treatment: Implications for health-care utilization. Addiction 2008, 103:1801-1808.
15. Krystal J.H., Cramer J.A., Krol W.F., Kirk G.F., Rosenheck R.A. Naltrexone in the treatment of alcohol dependence. New England Journal of Medicine 2001, 345:1734-1739.
16. Lee J.D., Grossman E., DiRocco D., Gourevitch M.N. Home buprenorphine/naloxone induction in primary care. Journal of General Internal Medicine 2009, 24:226-232.
17. Mark T.L., Kranzler H.R., Song X., Bransberger P., Poole V.H., Crosse S. Physicians' opinions about medications to treat alcoholism. Addiction 2003, 98:617-626.
18. McCaul M.E., Wand G.S., Stauffer R., Lee S.M., Rohde C.A. Naltrexone dampens ethanol-induced cardiovascular and hypothalamic-pituitary-adrenal axis activation. Neuropsychopharmacology 2001, 25:537-547.
19. Mertens J.R., Flisher A.J., Satre D.D., Weisner C.M. The role of medical conditions and primary care services in 5-year substance use outcomes among chemical dependency treatment patients. Drug and Alcohol Dependence 2008, 98:45-53.
20. Myrick H., Anton R.F., Li X., Henderson S., Randall P.K., Voronin K. Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people. Archives of General Psychiatry 2008, 65:466-475.
21. National Institute on Alcohol Abuse and Alcoholism Helping patients who drink too much: A clinician's guide, Updated 2005 Edition 2007, NIH Publication No. 07-3769. Retrieved February 24, 2010, from. http://pubs.niaaa.nih.gov/publications/Practitioner/CliniciansGuide2005/guide.pdf.
22. O'Malley S.S., Garbutt J.C., Gastfriend D.R., Dong Q., Kranzler H.R. Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment. Journal of Clinical Psychopharmacology 2007, 27:507-512.
23. O'Malley S.S., Rounsaville B.J., Farren C., Namkoong K., Wu R., Robinson J., et al. Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: A nested sequence of 3 randomized trials. Archives of Internal Medicine 2003, 163:1695-1704.
24. Oslin D.W., Lynch K.G., Pettinati H.M., Kampman K.M., Gariti P., Gelfand L., et al. A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention. Alcoholism: Clinical and Experimental Research 2008, 32:1299-1308.
25. Shah N.R., Hirsch A.G., Zacker C., Wood G.C., Schoenthaler A., Ogedegbe G., et al. Predictors of first-fill adherence for patients with hypertension. American Journal of Hypertension 2009, 22:392-396.
26. Sobell L.C., Sobell M.B. Alcohol timeline followback users' manual 1995, Addiction Research Foundation, Toronto, ON.
27. Srisurapanont M., Jarusuraisin N. Naltrexone for the treatment of alcoholism: A meta-analysis of randomized controlled trials. International Journal of Neuropsychopharmacology 2005, 8:267-280.
28. Substance Abuse and Mental Health Services Administration, Office of Applied Studies Results from the 2007 National Survey on Drug Use and Health: National Findings. NSDUH Series H-34, DHHS Publication No. SMA 08-4343 2008, Rockville, MD: DHHS.
29. Substance Abuse and Mental Health Services Administration, Office of Applied Studies Treatment Episode Data Set (TEDS) Highlights-2007 National Admissions to Substance Abuse Treatment Services. OAS Series #S-45, HHS Publication No. SMA 09-4360 2009, Rockville, MD: DHHS.
30. World Health Organization and World Organization of Fmily Doctors (Wonca) Integrating mental health into primary care-A global perspective 2008, Retrieved from. http://www.who.int/mental_health/Mental%20health%20+%20primary%20care-%20final%20low-res%20140908.pdf.